-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Entresto has been successful in improving the severity of symptoms and heart function in patients with heart failure (HFpEF) with constant blood test scores, according to a new report published at the annual meeting of the European Society of Cardiology.
it is known that Entresto improved levels of NT-proBNP (an indicator of the severity of heart failure in patients) in the patient's serum at the 24th week of the trial, but this result was also observed in patients who took prostataine, ACEI inhibitors or placebos.
showed no significant lead over other drug groups in improving patients' six-minute walking distance.
at the secondary endpoint, the drug improved quality of life after 24 weeks, but failed to surpass the control group.
Istresto is a combination of salutan and brain morphine enzyme inhibitor sacubitril, Novarma hopes Endresto will be the first drug approved for treatment of HFpEF patients.
based on current trial results, the drug's future appears to be mixed.
understood that Entresto was approved by the FDA in July 2015 to treat patients with decreased blood score and heart failure (HFrEF).
July 2017, the drug was approved for sale in China.
June 2019, Novaral announced the full results of the Entresto Drug Global Phase III PARAGON-HF study.
The trial was a randomized, double-blind, parallel group, and actively controlled controlled controlled controlled trial in which a total of 4,822 patients with HFpEF heart failure were recruited, and the trial assessed the efficacy and safety of Endresto and the active drug control group python in HFpEF patients.
trial results showed that Entresto reduced the overall (first and relapsed) indicators of heart failure hospitalization and cardiovascular (CV) death by 13 percent, which was not statistically significant.
that although the study was mis-reported, it was still promising. later this year, however, Novart noted that the subgroup analysis of the trial could provide a basis for future research and more limited approval, as the data appear to resonate with cardiologists, analysts at
SVB Leerink said.
said in November that patients with a blood test score of less than 57 percent had a higher clinical response to Enteresto than those with a shot score above that threshold.
, Entresto's position as the field's leading heart failure drug among cardiologists could provide good news for its future sales.
In a July doctor survey, SVB Leerink analysts found that doctors were generally positive about Entersto's clinical efficacy in HFrEF patients and generally believed that sales of the drug would grow rapidly over the next few years as more doctors tended to prescribe Enterto.
competitors, AstraZene Cazorlan's SGLT2 inhibitor, Farxiga, received the FDA's first approval in May to treat HFrEF patients with type 2 diabetes or not.
, Lilly and Grigg Ingham are also working on the approval of SGLT2 inhibitor Jardiance.
, Entresto is Novartic's latest growth driver, with the drug up 74 percent in the fourth quarter of 2019 to $1.7 billion for the full year, up 68 percent from a year earlier, and total revenue of $569 million in the first quarter of 2020.
source: 1.Novartis PARAGON-HF trial suggests entresto® benefit in HFpEF patients but narrowly misses primary endpoint 2.ESC: Novartis' 'novartis' esto racks up heart study win-it's a mixed one.